Catherine Shaffer

2 months ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Optellum and Volpara Health teamed up this week to market artificial intelligence (AI)-driven cancer detection tools to hospitals in the US, pairing Optellum's lung cancer capabilities with Volpara's suite of tools for analyzing breast imaging. Oxford, England-based Optellum develops AI-driven solutions for lung cancer. Its Virtual Nodule Clinic analyzes imaging data to determine the likelihood that a lung nodule is cancerous.

2 months ago | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – Memorial Sloan Kettering Cancer Center has built a data infrastructure that now represents 140,000 tumor samples and 100,000 cancer patients and is using it to train machine learning models that can effectively pull critical information from unstructured electronic health records using natural language processing (NLP). While the models are still in early development, MSK researchers hope to harness the database in the future to make individualized cancer treatment decisions.

Feb 6, 2025 | precisionmedicineonline.com | Catherine Shaffer

NEW YORK – AstraZeneca is hoping for a positive readout this year from the SERENA-6 Phase III trial of its investigational complete estrogen receptor antagonist camizestrant, which could set the drug up to be combined with other molecules in the company's growing breast cancer franchise. AstraZeneca executives outlined expectations for camizestrant in a call Thursday morning with investors to discuss its full year 2024 and fourth quarter financial results.

Nov 27, 2024 | 360dx.com | Catherine Shaffer

NEW YORK – Ataraxis AI is developing artificial intelligence-driven digital pathology tests that it believes may provide faster, more accurate, and more cost-effective answers to clinical questions about cancer patients' outcomes and recurrences than traditional molecular tests on the market.

Oct 31, 2024 | 360dx.com | Catherine Shaffer

NEW YORK – SkylineDx has scaled up efforts to drive adoption of its Merlin test in recent months after several new studies showcased its ability to predict which patients with cutaneous melanoma are at risk of metastasis and which can safely forgo sentinel lymph node biopsy surgery. The Merlin test, also called CP-GEP, combines clinicopathologic variables with gene-expression profiling via qPCR to stratify patients with cutaneous melanoma as high risk or low risk of nodal metastasis.